Proceedings from a CME symposium held at the 2019 ASCO Annual Meeting. Featuring perspectives from Prof Fabrice André and Drs Virginia Kaklamani, Mark D Pegram, Hope S Rugo, Sara M Tolaney and Tiffany A Traina.

Investigator Perspectives on the Current and Future Management of Newly Diagnosed Ovarian Cancer — Part 1: Our most recent one-on-one interview with Dr Monk featuring emerging research and cases from his practice:

• Guidelines for germline and somatic BRCA testing in ovarian cancer (00:00)
• Incidence and potential impact of other clinically relevant genetic abnormalities on clinical decision-making in the front-line setting (2:52)
• Patient selection for neoadjuvant systemic therapy in clinical practice (5:31)
• Bevacizumab as a component of neoadjuvant systemic therapy for patients with ovarian cancer (7:52)
• Clinical approach to patient selection for neoadjuvant chemotherapy; perspective on optimal schedule and dose of neoadjuvant regimen (10:47)
• Importance of the extent of response to neoadjuvant chemotherapy in the timing of debulking surgery (13:57)
• Therapeutic approach for patients with newly diagnosed ovarian cancer, germline BRCA mutations, bilateral pleural effusions and liver metastases (16:17)
• Lingering controversies regarding the use of intraperitoneal chemotherapy for ovarian cancer (18:30)
• GOG-0252: Design and results of a Phase III trial of intravenous or intraperitoneal chemotherapy, each in combination with bevacizumab, for advanced ovarian cancer (20:40)
• Perspective on the recent FDA approval of bevacizumab in combination with carboplatin and paclitaxel followed by single-agent bevacizumab for Stage III or IV epithelial ovarian cancer after initial surgical resection (22:29)
• Importance of disease stage and amount of residual disease in the decision to use bevacizumab as a component of primary therapy after debulking surgery (25:21)
• Evaluating the optimal duration of maintenance bevacizumab (26:39)
• Effect of bevacizumab on progression-free survival for patients with high-risk disease (28:19)
• Risk of bevacizumab-associated gastrointestinal perforation; contraindications to bevacizumab (29:57)
• Perspective on combining a PARP inhibitor with bevacizumab as maintenance therapy for patients with advanced platinum-sensitive ovarian cancer (32:15)
• PAOLA-1: An ongoing Phase III trial of olaparib combined with bevacizumab as maintenance therapy for patients with advanced ovarian cancer after first-line platinum-based chemotherapy in combination with bevacizumab (35:42)
• Practical approaches to mitigating carboplatin/paclitaxel-induced peripheral neuropathy (36:58)
• Comparison of treatment-associated neurotoxicity with nab paclitaxel and solvent-based paclitaxel (39:36)
• Clinical experience with bevacizumab for ovarian cancer; management of hypertension and proteinuria (41:08)
• Activity and ongoing investigation of anti-angiogenic agents alone or in combination with PARP inhibitors for advanced ovarian cancer (42:46)
• FDA breakthrough therapy designation for lenvatinib in combination with pembrolizumab for previously treated advanced microsatellite instability (MSI)-nonhigh/mismatch repair proficient endometrial cancer (44:14)
• Rationale for the design of ongoing studies combining immune checkpoint inhibitors with anti-angiogenic agents and/or PARP inhibitors (45:47)
• Modulation of gut microbiome to enhance response to anti-PD-1 immunotherapy; impact of antibiotics on response to treatment with immune checkpoint inhibitors (49:00)

Select publications

Investigator Perspectives on the Current and Future Management of Newly Diagnosed Ovarian Cancer — Part 1: Our most recent one-on-one interview with Dr Monk featuring emerging research and cases from his practice.

Investigator Perspectives on the Current and Future Management of Newly Diagnosed Ovarian Cancer — Part 2: Our most recent one-on-one interview with Professor Ledermann featuring emerging research and cases from his practice.

Investigator Perspectives on the Current and Future Management of Newly Diagnosed Ovarian Cancer — Part 2: Our most recent one-on-one interview with Professor Ledermann featuring emerging research and cases from his practice:

• Biology and histopathologic subtypes of ovarian cancer (0:00)
• Structure of gynecologic oncology clinical practice in the United Kingdom (1:58)
• Approach to mutation testing for patients with newly diagnosed ovarian cancer (4:06)
• Primary debulking surgery versus neoadjuvant systemic therapy in the up-front management of advanced ovarian cancer (6:51)
• Value of neoadjuvant chemotherapy versus up-front debulking surgery followed by adjuvant chemotherapy (10:08)
• Higher incidence of visceral metastases in patients with ovarian cancer and BRCA1/2 mutations (13:02)
• Optimal timing of debulking surgery with (neo)adjuvant chemotherapy for newly diagnosed ovarian cancer (15:22)
• Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery for advanced ovarian cancer; duration of maintenance therapy with bevacizumab (16:42)
• ICON8: Results of a Phase III trial evaluating response to neoadjuvant weekly dose-dense chemotherapy as first-line therapy for epithelial ovarian cancer (19:18)
• Influence of performance status and age on the choice of neoadjuvant versus adjuvant chemotherapy (21:07)
• Activity and ongoing investigation of PARP inhibitors in combination with chemotherapy and/or bevacizumab and as maintenance therapy for patients with newly diagnosed ovarian cancer with and without germline BRCA mutations (23:12)
• Consideration of bevacizumab as a component of (neo)adjuvant systemic therapy for patients with ovarian cancer (26:41)
• Choosing between bevacizumab and olaparib after primary debulking surgery; importance of timely BRCA mutation analysis to aid in this decision (29:21)
• Progression-free survival benefit with bevacizumab in combination with and after chemotherapy for patients with surgically debulked disease (33:15)
• Incidence of gastrointestinal toxicities with up-front bevacizumab for ovarian cancer (36:28)
• Approach to discontinuation of maintenance bevacizumab before surgery (38:13)
• MSI/DNA mismatch repair testing in ovarian cancer (39:28)
• PARP inhibitor-associated insomnia (40:32)
• Case: A woman in her late 50s is diagnosed with Stage IV high-grade serous ovarian cancer with a germline BRCA1 mutation (42:05)
• Counseling patients with ovarian cancer with germline BRCA mutations who did not receive PARP inhibition as a component of initial therapy about potential use of these agents in future treatment (45:51)
• Impact of BRCA mutation status on patient prognosis and potential responsiveness to platinum-based chemotherapy (48:05)
• Case: A woman in her early 70s with Stage IV high-grade serous ovarian cancer with a germline BRCA1 mutation receives olaparib on the Phase III SOLO-1 trial (49:21)
• Case: A woman in her early 60s with suboptimally debulked Stage IV high-grade serous ovarian cancer receives adjuvant chemotherapy/bevacizumab followed by maintenance bevacizumab (53:03)
• Biologic rationale for and ongoing evaluation of anti-PD-1/PD-L1 antibodies in combination with PARP inhibitors for newly diagnosed ovarian cancer (56:35)
• Benefits and limitations of commercially available HRD (homologous recombination deficiency) testing platforms (59:37)

Select publications

Video proceedings from the sixth in a series of 6 integrated symposia held at the 2019 ONS Annual Congress. Featuring perspectives from Ms Kelly EH Goodwin, Dr Joel W Neal, Ms Judy Pagtama and Dr Anne S Tsao:

• Introduction (00:00)
  • Program overview: Dr Love
• EGFR-Mutated Metastatic Non-Small Cell Lung Cancer (NSCLC) (9:42)
• Case (Ms Pagtama): A man in his late 50s with Stage IV adenocarcinoma of the lung with an EGFR tumor mutation, a right pleural effusion and a single brain metastasis who received first-line osimertinib (28:51)
• Case (Ms Goodwin): A woman in her early 70s with Stage IV adenosquamous NSCLC with an EGFR tumor mutation who was found to have a MET amplification after disease progression on osimertinib (33:57)
• Immune Checkpoint Inhibitor Therapy for Metastatic NSCLC (41:29)
• Case (Ms Pagtama): A man in his mid-90s with Stage IV pan-wild-type adenocarcinoma of the lung and a high PD-L1 tumor proportion score who received pembrolizumab monotherapy (50:24)
• Case (Ms Goodwin): A man in his mid-60s with extensive metastatic adenocarcinoma of the lung who received carboplatin/pemetrexed/pembrolizumab (1:06:52)
• Immunotherapy as Consolidation After Chemoradiation Therapy for Locally Advanced NSCLC (1:15:58)
• Case (Ms Pagtama): A man in his early 70s with locally recurrent adenocarcinoma of the lung who received concurrent chemoradiation therapy followed by consolidation durvalumab (1:16:26)

Select publications

Video proceedings from the sixth in a series of 6 integrated symposia held at the 2019 ONS Annual Congress. Featuring perspectives from Ms Kelly EH Goodwin, Dr Joel W Neal, Ms Judy Pagtama and Dr Anne S Tsao.

Video proceedings from the fifth in a series of 6 integrated symposia held at the 2019 ONS Annual Congress. Featuring perspectives from Dr Erika Hamilton, Ms Elizabeth O’Reilly, Dr Hope S Rugo and Ms Gretchen Santos.

Video proceedings from the fifth in a series of 6 integrated symposia held at the 2019 ONS Annual Congress. Featuring perspectives from Dr Erika Hamilton, Ms Elizabeth O’Reilly, Dr Hope S Rugo and Ms Gretchen Santos:

• Introduction (00:00)
  • Program overview: Dr Love
• HER2-Positive Localized and Metastatic Breast Cancer (BC) (2:16)
• Case (Ms O’Reilly): A woman in her late 40s with ER-positive, HER2-positive Stage IIIB inflammatory BC who received neoadjuvant treatment, had significant residual disease at surgery and began adjuvant T-DM1 (9:04)
• Case (Ms Santos): A woman in her early 60s with ER-negative, HER2-positive BC who began 1 year of adjuvant trastuzumab/pertuzumab after mastectomy but was switched to T-DM1 (12:31)
• Case (Ms Santos): A woman in her early 40s with ER-positive, HER2-positive BC who received postadjuvant neratinib on the CONTROL study (38:38)
• Case (Ms O’Reilly): A woman in her early 60s initially diagnosed with ER-positive, HER2-negative BC presents with ER-positive, HER2-positive metastatic disease to the bone, liver and brain (43:41)
• ER-Positive, HER2-Negative Metastatic Disease (55:50)
• Case (Ms Santos): A premenopausal woman in her early 50s with widespread ER/PR-positive, HER2-negative metastatic BC to the bone who underwent ovarian ablation and received palbociclib/letrozole (1:5:38)
• Case (Ms O’Reilly): A woman in her early 50s with ER-positive metastatic BC who received multiple lines of systemic treatment, including abemaciclib monotherapy (1:15:53)
• Triple-Negative Metastatic BC (1:31:31)
• Case (Ms Santos): A woman in her mid-30s with metastatic triple-negative BC who experienced a good response to pembrolizumab (1:37:46)

Select publications

Video proceedings from the fourth in a series of 6 integrated symposia held at the 2019 ONS Annual Congress. Featuring perspectives from Dr Paul M Barr, Ms Josie Bazemore, Dr Nitin Jain and Ms Lynn Rich:

• Introduction (0m0s)
  • Program overview: Dr Love
• Newly Diagnosed Chronic Lymphocytic Leukemia (CLL): Observation versus Treatment (00:38)
• Case (Ms Bazemore): A woman in her early 60s with CLL with del(17p) and an IGHV mutation who was observed for 1 year before beginning treatment with ibrutinib (2:17)
• First-Line Treatment of CLL (6:58)
• Case (Ms Rich): A woman in her late 30s with newly diagnosed CLL who received FCR and has developed multiple infections after the completion of treatment (15:52)
• Case (Ms Bazemore): A man in his early 90s with CLL with unmutated IGHV who experienced a complete response to first-line obinutuzumab/chlorambucil (48:40)
• Relapsed/Refractory CLL (53:33)
• Case (Ms Rich): A man in his early 70s with relapsed CLL and a high tumor burden who initiated treatment with venetoclax (1:12:24)
• Case (Ms Bazemore): A man in his mid-60s with relapsed CLL who was admitted to receive venetoclax because of concerns with compliance (1:15:40)
• Case (Ms Rich): A man in his mid-70s with heavily pretreated CLL who was referred for hospice but is currently faring well off treatment (1:22:09)

Select publications